Kamada Declares Dividend, Signaling Confidence Amid Aggressive Growth

REHOVOT, Israel and HOBOKEN, N.J. – March 11, 2026 – Kamada Ltd. (NASDAQ: KMDA), a global biopharmaceutical company, announced a significant shift in its capital allocation strategy today, declaring a cash dividend of $0.25 per share following a year of robust financial performance. The move, part of a newly adopted annual dividend policy, signals a new stage of maturity for the company as it simultaneously balances shareholder returns with an ambitious agenda for growth and acquisitions.

The dividend, totaling approximately $14.4 million, will be paid on April 6, 2026, to shareholders of record as of March 23, 2026. This distribution is the first under a new policy where Kamada intends to return at least 50% of its annual net income to shareholders, a decision underpinned by strong 2025 financial results and what the company describes as a solid cash position.

“This dividend payment reinforces our confidence of the Company’s business prospects and liquidity to continue investing in our commercial growth, while aiming to secure new business development and M&A transactions, while also paying dividend to our shareholders,” stated Amir London, Kamada’s Chief Executive Officer, in the official announcement. “I would like to thank our shareholders for their continued support and trust in Kamada.”

A Foundation of Financial Strength

The decision to initiate a regular dividend is supported by a strong financial performance in 2025. Kamada reported total revenues of $180.5 million for the year, a 12% increase over 2024. More impressively, the company’s net income surged by 40% to $20.2 million, or $0.35 per diluted share. This profitability was driven by increased sales of key products like VARIZIG® and KEDRAB® in the United States, alongside growth in its distribution segment.

The company's cash flow from operations was a healthy $25.5 million in 2025, and it ended the year with a cash and equivalents balance of $75.5 million. This financial cushion provides the foundation for both the dividend and continued investment. While the company's fourth-quarter earnings per share of $0.06 missed some analyst expectations, leading to a minor pre-market stock dip, the overall annual performance paints a picture of a company on a solid growth trajectory.

For 2026, Kamada projects continued double-digit growth, with revenue guidance set between $200 million and $205 million and adjusted EBITDA forecasted to be between $50 million and $53 million, further bolstering the case for its newfound confidence.

A Strategic Pivot in the Biopharma Landscape

Kamada's adoption of a formal dividend policy is a noteworthy event in the biopharmaceutical sector, where many growth-stage companies historically prioritize reinvesting all profits back into research, development, and expansion. By committing to substantial shareholder returns, Kamada is positioning itself as a more mature entity, capable of both generating and distributing wealth.

This strategic pivot aligns it more with established pharmaceutical giants than with typical high-growth biotechs. The move could broaden its appeal to a new class of income-focused investors who may have previously overlooked the company. It demonstrates a belief that its business model is now stable and profitable enough to sustain both shareholder payouts and its aggressive growth initiatives without compromising either.

This is a significant departure from the company's past, which did not include a regular dividend payout. The formalization of this policy signals a long-term commitment and a belief in sustained profitability, a message that is likely to resonate positively with long-term shareholders.

Fueling an Ambitious Four-Pillar Growth Engine

Crucially, the dividend is not being presented as a slowdown in ambition. Instead, management frames it as a byproduct of a successful strategy that continues to fire on all cylinders. The company's growth is built upon four key pillars, each showing significant progress.

First, organic growth of its commercial portfolio remains strong. Sales of its FDA-approved plasma-derived products are climbing, with KEDRAB® sales reaching approximately $54 million in 2025. The company has also secured a minimum commitment of $90 million for KEDRAB from its partner Kedrion for 2026 and 2027.

Second, the third-party distribution business is expanding. Kamada has successfully launched biosimilar products in Israel and is making inroads into the Middle East and North Africa (MENA) region. This biosimilar portfolio alone is projected to generate $15 million to $20 million in annual sales within the next five years.

Third, and perhaps most critical to its long-term strategy, is the expansion of its plasma collection operations. Kamada is ramping up operations at three centers in Texas. Its Houston center, approved by the FDA in August 2025, is expected to generate $8 million to $10 million in annual revenue at full capacity. The San Antonio center is anticipated to receive FDA approval in the first half of 2026 and generate similar revenues. This vertical integration strategy is designed to secure its supply of specialty plasma, reduce costs, and create a new revenue stream from the sale of normal source plasma.

Finally, the company remains focused on mergers and acquisitions (M&A). With a strong balance sheet and the backing of its controlling shareholder, FIMI Opportunity Funds, Kamada is actively seeking deals to enhance its product portfolio and leverage its commercial infrastructure. The dividend, in this context, is a declaration that the company has the financial liquidity to pursue these transformative opportunities while still rewarding its investors directly.